Diffuse Large B Cell Lymphoma
269
61
89
67
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
20 trials with published results (7%)
Research Maturity
67 completed trials (25% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.4%
20 terminated out of 269 trials
77.0%
-9.5% vs benchmark
7%
19 trials in Phase 3/4
30%
20 of 67 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 67 completed trials
Clinical Trials (269)
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
SynKIR-310 for Relapsed/Refractory B-NHL